BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16258501)

  • 1. DNA hypermethylation status of multiple genes in soft tissue sarcomas.
    Kawaguchi K; Oda Y; Saito T; Yamamoto H; Takahira T; Kobayashi C; Tamiya S; Tateishi N; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2006 Jan; 19(1):106-14. PubMed ID: 16258501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.
    Lee KH; Lee JS; Nam JH; Choi C; Lee MC; Park CS; Juhng SW; Lee JH
    Langenbecks Arch Surg; 2011 Oct; 396(7):1017-26. PubMed ID: 21706233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z; Zhang H; Yang J; Hao T; Li S
    Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
    Kwong J; Lo KW; To KF; Teo PM; Johnson PJ; Huang DP
    Clin Cancer Res; 2002 Jan; 8(1):131-7. PubMed ID: 11801549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 inactivation in alveolar soft part sarcoma.
    Saito T; Oda Y; Kawaguchi K; Takahira T; Yamamoto H; Sakamoto A; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2003 Sep; 34(9):841-9. PubMed ID: 14562278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.
    Su Y; Yin L; Liu R; Sheng J; Yang M; Wang Y; Pan E; Guo W; Pu Y; Zhang J; Liang G
    Med Oncol; 2014 Feb; 31(2):784. PubMed ID: 24366688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients.
    Gonzalez-Gomez P; Bello MJ; Arjona D; Alonso ME; Lomas J; Amiñoso C; de Campos JM; Sarasa JL; Gutierrez M; Rey JA
    Cancer Genet Cytogenet; 2003 Apr; 142(1):21-4. PubMed ID: 12660028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection.
    Matsukura S; Soejima H; Nakagawachi T; Yakushiji H; Ogawa A; Fukuhara M; Miyazaki K; Nakabeppu Y; Sekiguchi M; Mukai T
    Br J Cancer; 2003 Feb; 88(4):521-9. PubMed ID: 12592365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.
    Choy KW; Pang CP; To KF; Yu CB; Ng JS; Lam DS
    Invest Ophthalmol Vis Sci; 2002 May; 43(5):1344-9. PubMed ID: 11980845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.
    Safar AM; Spencer H; Su X; Coffey M; Cooney CA; Ratnasinghe LD; Hutchins LF; Fan CY
    Clin Cancer Res; 2005 Jun; 11(12):4400-5. PubMed ID: 15958624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia.
    Rossi D; Capello D; Gloghini A; Franceschetti S; Paulli M; Bhatia K; Saglio G; Vitolo U; Pileri SA; Esteller M; Carbone A; Gaidano G
    Haematologica; 2004 Feb; 89(2):154-64. PubMed ID: 15003890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.
    Kim JI; Suh JT; Choi KU; Kang HJ; Shin DH; Lee IS; Moon TY; Kim WT
    Hum Pathol; 2009 Jul; 40(7):934-41. PubMed ID: 19356788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner.
    Su PF; Huang WL; Wu HT; Wu CH; Liu TY; Kao SY
    Oral Oncol; 2010 Oct; 46(10):734-9. PubMed ID: 20729138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas.
    Kawaguchi K; Oda Y; Takahira T; Saito T; Yamamoto H; Kobayashi C; Tamiya S; Oda S; Iwamoto Y; Tsuneyoshi M
    Oncol Rep; 2005 Feb; 13(2):241-6. PubMed ID: 15643505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma.
    Viswanathan M; Tsuchida N; Shanmugam G
    Int J Cancer; 2003 May; 105(1):41-6. PubMed ID: 12672028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
    Ye C; Shrubsole MJ; Cai Q; Ness R; Grady WM; Smalley W; Cai H; Washington K; Zheng W
    Oncol Rep; 2006 Aug; 16(2):429-35. PubMed ID: 16820927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer.
    Xiong HL; Liu XQ; Sun AH; He Y; Li J; Xia Y
    Asian Pac J Cancer Prev; 2013; 14(5):3139-42. PubMed ID: 23803092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
    Psofaki V; Kalogera C; Tzambouras N; Stephanou D; Tsianos E; Seferiadis K; Kolios G
    World J Gastroenterol; 2010 Jul; 16(28):3553-60. PubMed ID: 20653064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.